Astrazeneca plc
Research Astrazeneca plc (AZN) on Bullrun: valuation model: 25.5% overvalued, market cap USD 246.90B, P/E 47.8, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAZN
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal25.5% overvalued
- Market capUSD 246.90B
- P/E47.8
- Dividend yield1.4%
- Financial periodQ2 2026
- RevenueUSD 15.38B
- Net incomeUSD 2.51B
- Free cash flow-USD 240.00M
- Gross margin83.6%
Valuation Snapshot
Bullrun's latest valuation model marks Astrazeneca plc as 25.5% overvalued; latest market cap is USD 246.90B; P/E is 47.8; dividend yield is 1.4%.
Peer valuation comparison
Latest P/E is 47.81x versus a Healthcare sector median of 24.61x (94.3% above).
Latest dividend yield is 1.36% versus a Healthcare sector median of 1.84% (26.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 58.74B | USD 10.23B | USD 8.67B | 81.9% | 6.54 | USD 5.71B | USD 29.15B | USD 48.67B |
| FY2024 | USD 54.07B | USD 7.04B | USD 7.28B | 81.1% | 4.5 | USD 5.49B | USD 30.11B | USD 40.79B |
| FY2023 | USD 45.81B | USD 5.96B | USD 6.57B | 82.0% | 3.81 | USD 5.84B | USD 28.41B | USD 39.14B |
| FY2022 | USD 44.35B | USD 3.29B | USD 7.24B | 72.1% | 2.11 | USD 6.17B | USD 29.14B | USD 37.04B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 246.90B | 47.8 | 1.4% | 2.15 |
| 2025 | 2025-12-31 | USD 285.12B | 56.1 | 1.7% | 3.13 |
| 2024 | 2024-12-31 | USD 203.13B | 58.2 | 2.3% | 2.97 |
| 2023 | 2023-12-29 | USD 208.78B | 71.3 | 2.2% | 2.9 |
| 2022 | 2022-12-30 | USD 210.12B | 208.6 | 2.1% | 2.9 |
| 2021 | 2021-12-31 | USD 180.51B | 832.1 | 2.4% | 2.8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.15 USD, yield 1.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 3.13 USD |
| FY2024 | 2.97 USD |
| FY2023 | 2.9 USD |
| FY2022 | 2.9 USD |
About Astrazeneca plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
ETFs that hold Astrazeneca plc
Astrazeneca plc is one of the ten largest holdings of 187 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| Amundi Core Stoxx Europe 600 UCITS ETF Acc | 1.91% | 0.07% |
| iShares Core FTSE 100 UCITS ETF (GBP Dist) | 8.41% | 0.07% |
| iShares Core MSCI Europe UCITS ETF EUR (Acc) | 2.00% | 0.12% |
| iShares STOXX Europe 600 UCITS ETF (DE) EUR (Dist) | 1.59% | 0.20% |
| iShares Core MSCI Europe UCITS ETF EUR (Dist) | 2.00% | 0.12% |
| Xtrackers MSCI World ex USA UCITS ETF 1C USD | 1.15% | 0.15% |
| Vanguard FTSE 100 UCITS ETF | 8.47% | 0.09% |
| Amundi Core MSCI Europe UCITS ETF DR | 1.80% | 0.12% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Astrazeneca plc overvalued or undervalued?
Bullrun's valuation model currently marks Astrazeneca plc as 25.5% overvalued.
What is Astrazeneca plc's market cap?
Astrazeneca plc's market capitalization is USD 246.90B.
What is Astrazeneca plc's P/E ratio?
Astrazeneca plc's price-to-earnings (P/E) ratio is 47.8.
Does Astrazeneca plc pay a dividend?
Astrazeneca plc has a dividend yield of 1.4%.
What does Astrazeneca plc do?
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.